Avacta : Preliminary Results for the Year Ended 31 December 2023

Avacta appoints new Chief Executive Officer Christina Coughlin, MD PhD


Clinical proof-of-concept demonstrated for Avacta's lead programme AVA6000 and proof-of-mechanism for the...

Related Keywords

San Diego ,California ,United States ,United Kingdom ,American ,Shaun Chilton ,Coris Bioconcept ,Eliot Forster ,Christina Coughlin ,Alastair Smith ,Avacta Group ,Head Of Research Development ,Diagnostics Division ,Avacta Diagnostics Division ,Therapeutics Division ,American Association For Cancer Research ,Chief Executive Officer Christina Coughlin ,American Association ,Cancer Research ,Fibroblast Activation Protein ,Xell Therapeutics ,Daewoong Pharmaceutical ,Chief Business Officer ,Chief Executive Officer ,Non Executive Director ,Clinical Proof ,Belgium Based Coris Bioconcept ,Launch Diagnostics ,Markets ,